
Local vs Central Testing: What It Means for Ensitrelvir COVID-19 PEP
Florin Draica, MD, MBA, of Shionogi on ensitrelvir PEP outcomes in patients infected at baseline despite negative antigen tests.
Captions are auto-generated.
Differentiating between a local test and a central test makes a significant difference in diagnosing a
The nuance for administering this drug was evaluated using patient data from the SCORPIO-PEP study, which supported its FDA approval, in exploratory analyses presented at
What makes these findings substantial is that this scenario reflects the real world, where patients will mostly rely on an at-home antigen test, he explained. And although ensitrelvir is not approved for the treatment of COVID-19 and was administered before researchers or patients knew they were infected, those who were infected at the time of receipt experienced a numerically lower viral load, lower symptom burden, and fewer severe symptoms compared with placebo.1
“And these exploratory findings then provide additional insights into the outcomes associated with the early administration of ensitrelvir during that period between exposure and symptom onset,” Draica said.
Despite the findings, he emphasized that vaccination remains critical for preventing COVID-19, but vaccination by itself “may not necessarily stop infection completely, particularly when there are new emerging variants,” Draica explained. He added that immunity also wanes over time, and for those who don't develop a sufficient immune response to the virus, “Xocova provides an additional opportunity to intervene after a known exposure,” he said.
References
1. IDWeek 2026: new exploratory analyses evaluate XOCOVA® (ensitrelvir) following COVID-19 exposure, including breakthrough infections and infections present at baseline. News release. Shionogi. October 2026. Accessed November 18, 2026.
Related to this article








